Barnett & Company’s AstraZeneca AZN Stock Holding History

Barnett & Company’s Portfolio AZN Stock Details AZN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q1	–	Sell	-58	Closed	-$7K	–	113
2021 Q4	$7K	Buy	+58	New	+$6.83K	﹤0.01%	209
2021 Q2	–	Sell	-13,750	Closed	-$1.37M	–	226
2021 Q1	$1.37M	Buy	13,750 +1,000	+8%	+$101K	0.73%	38
2020 Q4	$1.27M	Sell	12,750 -2,100	-14%	-$222K	0.8%	34
2020 Q3	$1.63M	Buy	14,850 +750	+5%	+$83.4K	1.16%	23
2020 Q2	$1.49M	Buy	+14,100	New	+$1.46M	1.21%	22
2017 Q4	–	Sell	-81	Closed	-$5K	–	317
2017 Q3	$5K	Hold	81	–	–	﹤0.01%	303
2017 Q2	$6K	Hold	81	–	–	﹤0.01%	322
2017 Q1	$5K	Hold	81	–	–	﹤0.01%	310
2016 Q4	$4K	Hold	81	–	–	﹤0.01%	351
2016 Q3	$5K	Hold	81	–	–	﹤0.01%	357
2016 Q2	$5K	Hold	81	–	–	﹤0.01%	344
2016 Q1	$5K	Buy	+81	New	+$4.87K	﹤0.01%	361

Other funds holding AZN

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

Primecap Management Pasadena, California $127B AUM 44.11% 1-Year Est. Return

Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return

Fisher Asset Management Camas, Washington $295B AUM 31.6% 1-Year Est. Return

GQG Partners Ft. Lauderdale, Florida $63.1B AUM 23.07% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return

CIBC Private Wealth Group Atlanta, Georgia $59.2B AUM 20.62% 1-Year Est. Return

Barnett & Company's AZN Position: Q1 2022 in Review

Barnett & Company sold out of AstraZeneca (AZN) in Q1 2022, closing a stake of 58 shares — an estimated $7K sold.

Barnett & Company first reported a position in AZN in Q1 2016 and held it in 12 quarters. The position peaked at $1.63M in Q3 2020. 981 funds tracked by Wall St. Rank hold AZN as of Q1 2022.

Barnett & Company reported no remaining AstraZeneca position as of Q1 2022 after selling out during the quarter.
Barnett & Company sold 58 AstraZeneca shares in Q1 2022, an estimated $7K.
Barnett & Company first reported a position in AstraZeneca in Q1 2016 and held it in 12 quarters.
Barnett & Company's AstraZeneca position peaked at $1.63M in Q3 2020.
981 funds tracked by Wall St. Rank held AstraZeneca as of Q1 2022.

Based on Barnett & Company's 13F filing for Q1 2022, filed 28 Apr 2022.